

David P Breen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10747836/publications.pdf>

Version: 2024-02-01

48
papers

2,965
citations

304368

22
h-index

223531

46
g-index

49
all docs

49
docs citations

49
times ranked

4655
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial. <i>Lancet, The</i> , 2014, 383, 1138-1146.	6.3	368
2	Characterizing mild cognitive impairment in incident Parkinson disease. <i>Neurology</i> , 2014, 82, 308-316.	1.5	359
3	Sleep and Circadian Rhythm Regulation in Early Parkinson Disease. <i>JAMA Neurology</i> , 2014, 71, 589.	4.5	333
4	Serum immune markers and disease progression in an incident Parkinson's disease cohort (ICICLE-PD). <i>Movement Disorders</i> , 2016, 31, 995-1003.	2.2	211
5	Bioinformatics-Based Identification of Expanded Repeats: A Non-reference Intronic Pentamer Expansion in RFC1 Causes CANVAS. <i>American Journal of Human Genetics</i> , 2019, 105, 151-165.	2.6	170
6	Cognitive decline and quality of life in incident Parkinson's disease: The role of attention. <i>Parkinsonism and Related Disorders</i> , 2016, 27, 47-53.	1.1	133
7	Prediction of cognition in Parkinson's disease with a clinical "genetic score: a longitudinal analysis of nine cohorts. <i>Lancet Neurology, The</i> , 2017, 16, 620-629.	4.9	131
8	Genetic impact on cognition and brain function in newly diagnosed Parkinson's disease: ICICLE-PD study. <i>Brain</i> , 2014, 137, 2743-2758.	3.7	127
9	Genomewide association study of Parkinson's disease clinical biomarkers in 12 longitudinal patients' cohorts. <i>Movement Disorders</i> , 2019, 34, 1839-1850.	2.2	122
10	Genetic risk of Parkinson disease and progression:. <i>Neurology: Genetics</i> , 2019, 5, e348.	0.9	109
11	The Addenbrooke's Cognitive Examination for the differential diagnosis and longitudinal assessment of patients with parkinsonian disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 544-551.	0.9	94
12	Stability of mild cognitive impairment in newly diagnosed Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 648-652.	0.9	88
13	Neuroendocrine abnormalities in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 176-185.	0.9	70
14	Determinants of delayed diagnosis in Parkinson's disease. <i>Journal of Neurology</i> , 2013, 260, 1978-1981.	1.8	65
15	Hypothalamic volume loss is associated with reduced melatonin output in Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 1062-1066.	2.2	59
16	Peripheral innate immune and bacterial signals relate to clinical heterogeneity in Parkinson's disease. <i>Brain, Behavior, and Immunity</i> , 2020, 87, 473-488.	2.0	58
17	Essential tremor plus is more common than essential tremor: Insights from the reclassification of a cohort of patients with lower limb tremor. <i>Parkinsonism and Related Disorders</i> , 2018, 56, 109-110.	1.1	53
18	Anxiety is associated with cognitive impairment in newly-diagnosed Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2017, 36, 63-68.	1.1	50

#	ARTICLE	IF	CITATIONS
19	Impact of <i>GBA1</i> variants on long-term clinical progression and mortality in incident Parkinsonâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 695-702.	0.9	48
20	Excessive daytime sleepiness and its risk factors in incident Parkinson's disease: TableÂ1. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 233-234.	0.9	47
21	Addenbrooke's Cognitive Examinationâ€Revised for mild cognitive impairment in Parkinson's disease. Movement Disorders, 2012, 27, 1173-1177.	2.2	38
22	Cerebrospinal Fluid Cytokines and Neurodegenerationâ€Associated Proteins in Parkinson's Disease. Movement Disorders, 2020, 35, 1062-1066.	2.2	33
23	New awakenings: current understanding of sleep dysfunction and its treatment in Parkinsonâ€™s disease. Journal of Neurology, 2020, 267, 288-294.	1.8	25
24	Quality of Life and Mild Cognitive Impairment in Early Parkinsonâ€™s Disease: Does Subtype Matter?. Journal of Parkinson's Disease, 2015, 4, 331-336.	1.5	22
25	The Impact of Deep Brain Stimulation on Sleep and Olfactory Function in Parkinsonâ€™s Disease. The Open Neurology Journal, 2015, 9, 70-72.	0.4	20
26	Anticholinergic Load: Is there a Cognitive Cost in Early Parkinsonâ€™s Disease?. Journal of Parkinson's Disease, 2015, 5, 743-747.	1.5	17
27	Validation of a UPDRS-/MDS-UPDRS-based definition of functional dependency for Parkinson's disease. Parkinsonism and Related Disorders, 2020, 76, 49-53.	1.1	13
28	Sleepâ€related motor and behavioral disorders: Recent advances and new entities. Movement Disorders, 2018, 33, 1042-1055.	2.2	12
29	Soft tissue plasmacytomas in multiple myeloma. Lancet, The, 2017, 390, 2083.	6.3	9
30	Functional movement disorders arising after successful deep brain stimulation. Neurology, 2018, 90, 931-932.	1.5	9
31	Confirmation of brainstem death. Practical Neurology, 2016, 16, 129-135.	0.5	8
32	Exogenous melatonin for Parkinsonâ€™s disease: â€Waking upâ€™ to the need for further trials. Parkinsonism and Related Disorders, 2016, 29, 121-122.	1.1	7
33	Toscana virus encephalitis following a holiday in Sicily. Practical Neurology, 2016, 16, 139-141.	0.5	7
34	The clinical significance of lower limb tremors. Parkinsonism and Related Disorders, 2019, 65, 165-171.	1.1	7
35	Successful pallidotomy for post-hyperglycemic hemichorea-ballism. Parkinsonism and Related Disorders, 2019, 61, 228-230.	1.1	6
36	Twinkle-associated familial parkinsonism with Lewy pathology. Neurology, 2020, 95, 644-647.	1.5	6

#	ARTICLE	IF	CITATIONS
37	Mild dopa-responsive dystonia in heterozygous tyrosine hydroxylase mutation carrier: Evidence of symptomatic enzyme deficiency?. <i>Parkinsonism and Related Disorders</i> , 2020, 71, 44-45.	1.1	6
38	Tracking the course of prodromal Parkinson's disease. <i>Brain</i> , 2017, 140, 259-262.	3.7	5
39	The Central Clock in Patients With Parkinson Disease—Reply. <i>JAMA Neurology</i> , 2014, 71, 1456.	4.5	4
40	Reversible cerebral vasoconstriction syndrome as a cause of thunderclap headache: a retrospective case series study. <i>American Journal of Emergency Medicine</i> , 2015, 33, 859.e3-859.e6.	0.7	4
41	Infantile-onset hand dystonia with intellectual disability. <i>Neurology</i> , 2018, 90, 333-335.	1.5	3
42	Caregiving concerns and clinical characteristics across neurodegenerative and cerebrovascular disorders in the Ontario neurodegenerative disease research initiative. <i>International Journal of Geriatric Psychiatry</i> , 2022, 37, .	1.3	3
43	Î±-Synuclein strains in multiple system atrophy: A product of their environment?. <i>Movement Disorders</i> , 2018, 33, 1270-1270.	2.2	2
44	Mild dopa-responsive dystonia in heterozygous tyrosine hydroxylase mutation carrier: Evidence of symptomatic enzyme deficiency? Response from the authors. <i>Parkinsonism and Related Disorders</i> , 2020, 74, 80.	1.1	2
45	Anti-collapsin response mediator protein 5 encephalitis masquerading as a low-grade brain tumour. <i>Practical Neurology</i> , 2016, 16, 376-380.	0.5	1
46	CLIPPERS: A Treatable Cause of Spastic Ataxia. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 212-214.	0.8	1
47	Beware temporal arteritis that does not respond promptly to steroids. <i>Age and Ageing</i> , 2010, 39, 140-140.	0.7	0
48	Exploiting the aggregation properties of alpha-synuclein for diagnostic purposes. <i>Movement Disorders</i> , 2017, 32, 106-106.	2.2	0